Research article

The relationship of the factor V Leiden mutation or the deletion-deletion polymorphism of the angiotensin converting enzyme to postoperative thromboembolic events following total joint arthroplasty

Craig J Della Valle MD¹ , Paul S Issack¹ , Avi Baitner¹ , David J Steiger² , Carrie Fang¹ and Paul E Di Cesare¹

¹  Musculoskeletal Research Center, Room 1500 NYU-Hospital for Joint Diseases Department of Orthopaedic Surgery, 301 East 17th Street New York, USA

²  Department of Medicine New York University-Hospital for Joint Diseases 301 East 17th Street New York, USA

author email corresponding author email

BMC Musculoskeletal Disorders 2001, 2:1doi:10.1186/1471-2474-2-1

Published:	5 April 2001

Abstract

Background

Although all patients undergoing total joint arthroplasty are subjected to similar risk factors that predispose to thromboembolism, only a subset of patients develop this complication. The objective of this study was to determine whether a specific genetic profile is associated with a higher risk of developing a postoperative thromboembolic complication. Specifically, we examined if the Factor V Leiden (FVL) mutation or the deletion polymorphism of the angiotensin-converting enzyme (ACE) gene increased a patient's risk for postoperative thromboembolic events. The FVL mutation has been associated with an increased risk of idiopathic thromboembolism and the deletion polymorphism of the ACE gene has been associated with increased vascular tone, attenuated fibrinolysis and increased platelet aggregation.

Methods

The presence of these genetic profiles was determined for 38 patients who had a postoperative symptomatic pulmonary embolus or proximal deep venous thrombosis and 241 control patients without thrombosis using molecular biological techniques.

Results

The Factor V Leiden mutation was present in none of the 38 experimental patients and in 3% or 8 of the 241 controls (p = 0.26). Similarly there was no difference detected in the distribution of polymorphisms for the ACE gene with the deletion-deletion genotype present in 36% or 13 of the 38 experimental patients and in 31% or 74 of the 241 controls (p = 0.32).

Conclusions

Our results suggest that neither of these potentially hypercoaguable states are associated with an increased risk of symptomatic thromboembolic events following total hip or knee arthroplasty in patients receiving pharmacological thromboprophylaxis.